Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
NCT07109297
·
clinicaltrials.gov ↗
PHASE4
Phase
ACTIVE_NOT_RECRUITING
Status
110
Enrollment
INDUSTRY
Sponsor class
Conditions
RSV Immunization
Interventions
BIOLOGICAL:
Nirsevimab
Sponsor
Sanofi